Is Bliss GVS Pharma overvalued or undervalued?

As of 10 July 2025, Bliss GVS Pharma's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently deemed undervalued, particularly when considering its PE ratio of 19.29, EV to EBIT of 15.43, and a PEG ratio of 0.00, which suggests strong growth potential relative to its price.
In comparison to its peers, Bliss GVS Pharma's valuation metrics are more favorable, especially when contrasted with Sun Pharma, which has a PE ratio of 34.91 and an EV to EBITDA of 24.66, categorizing it as expensive. Additionally, Dr. Reddy's Labs, another attractive peer, has a PE of 18.58 and an EV to EBITDA of 12.27, reinforcing Bliss GVS Pharma's competitive positioning in the market. Notably, while the stock has underperformed the Sensex year-to-date, it has delivered a robust 38.96% return over the past year, further supporting its undervalued status.